Table 1.
Final population PK model parameter estimates of tremelimumab from the DETERMINE trial
| Model parameter | Θ (Median) | RSE (Θ) (%) | BSV (Ω) (%) | RSE (Ω) (%) |
|---|---|---|---|---|
| CL (L/day) | 0.310 | 4.62 | 38.0 | 8.54 |
| V1 (L) | 3.85 | 1.91 | 32.5 | 16.5 |
| V2 (L) | 1.72 | 19.4 | 25.2 | 84.6 |
| Q (L/day) | 0.273 | 42.8 | ||
| CV% (proportional ε) | 37.7% | 4.92 |
BSV, between‐subject variability of parameter with random effect assumed normally‐distributed with mean 0 and variance Ω2; CL, clearance; CV%, coefficient of variation percentage; PK, pharmacokinetic; RSE, relative standard error obtained from $COVARIANCE step in NONMEM; V, volume of distribution.